Jariya Taylor

Jariya Taylor serves as a primary procurement lead within the CDC Office of Acquisition Services, responsible for managing complex acquisitions that enable the agency’s mission to safeguard public health through scientific and operational capabilities. She oversees the acquisition of critical biomedical, diagnostic, and data infrastructure solutions, with a focus on supporting laboratory diagnostics, infectious disease surveillance, and public health research systems. Her work ensures timely access to high-integrity products and services essential for rapid response to emerging health threats, aligning closely with the CDC’s strategic priorities in biosafety, epidemiological data systems, and clinical readiness. Taylor maintains strong, sustained relationships with key industry partners including General Dynamics Information Technology, GlaxoSmithKline, Cepheid, MRIGLOBAL, and the New York City Health & Hospitals Corporation. These partnerships reflect a preference for established, high-capacity vendors capable of delivering scalable, regulatory-compliant solutions in pharmaceutical manufacturing, diagnostic testing, and health informatics. Her contracting approach emphasizes technical rigor, compliance with federal biosafety standards, and performance-based outcomes, often involving long-term service agreements and complex delivery orders. Her procurement activity is exclusively non-set-aside, with no use of 8(a), HUBZone, SDVOSB, or other socioeconomic programs, reflecting a mission-driven focus on securing the highest-capability vendors regardless of business size. This approach prioritizes technical expertise and operational readiness over socioeconomic preferences, ensuring rapid deployment of mission-critical capabilities during public health emergencies. Taylor’s portfolio is dominated by NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 513210 (Software Publishers), underscoring her specialization in procuring clinical-grade pharmaceuticals, diagnostic assays, laboratory reagents, and health data analytics platforms. She routinely manages acquisitions involving FDA-regulated products, CLIA-compliant testing systems, and interoperable public health information systems, demonstrating deep expertise in the intersection of life sciences, regulatory compliance, and digital health infrastructure.